Oxaliplatine Fresenius Kabi (Oxaliplatin)

Oxaliplatin exerts its anticancer effect by forming covalent bonds with DNA, creating platinum‑DNA adducts that distort the double helix. This interferes with DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death, especially in rapidly dividing tumor cells.

The dose of oxaliplatin is individualized by the prescribing oncologist based on the specific indication, patient weight, renal function, and treatment protocol. Dosing schedules are defined in clinical guidelines and must be determined by a qualified healthcare professional.

Oxaliplatin is contraindicated during pregnancy and lactation. Pre‑clinical and clinical data indicate potential fetal toxicity and the drug can be excreted in breast milk, posing risks to the infant. Women of child‑bearing potential should use effective contraception while receiving therapy.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Oxaliplatin shares the DNA‑cross‑linking mechanism of other platinum agents but generally has a more favorable renal toxicity profile than cisplatin. However, oxaliplatin is associated with a higher incidence of peripheral neuropathy. Choice of agent depends on tumor type, patient comorbidities, and the toxicity spectrum most acceptable for the individual.

The product should be stored at room temperature, preferably below 25 °C, in its original packaging to protect from light and moisture. Once reconstituted, the solution must be used within the time frame specified in the product label and kept protected from excessive heat.

Oxaliplatin is given as an intravenous infusion, usually over 2 hours. The infusion is performed in a clinical setting where vital signs can be monitored. Dosing intervals vary by regimen, commonly every two weeks, but the exact schedule is determined by the treating physician.

Serious risks include severe allergic or anaphylactic reactions, febrile neutropenia, interstitial pneumonitis, and cardiac arrhythmias. Patients should be monitored closely for signs of hypersensitivity, fever with low white‑cell counts, respiratory difficulty, or irregular heart rhythms, and treatment should be halted if any occur.

Oxaliplatin is contraindicated in patients with known hypersensitivity to the drug or other platinum compounds, those with severe renal or hepatic impairment, pregnant or nursing women, and individuals with uncontrolled cardiac conditions. Clinical judgment is required for patients with moderate organ dysfunction.